Nov 12 (Reuters) - CUREVAC NV 5CV.DE :
* CUREVAC ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER
AND
FIRST NINE MONTHS OF 2024 AND PROVIDES BUSINESS UPDATE
* EUR 400 MILLION UPFRONT PAYMENT FROM RESTRUCTURED GSK
COLLABORATION REFLECTED IN FINANCIALS, CASH POSITION INCREASED
TO EUR 551 MILLION; EXPECTED CASH RUNWAY RE-AFFIRMED INTO 2028
* APPOINTMENT AXEL MALKOMES AS NEW CFO EFFECTIVE NOVEMBER 11
* CORPORATE REDESIGN ON TRACK WITH 30% WORKFORCE REDUCTION,
EXPECTED TO YIELD SIGNIFICANT ANNUAL COST SAVINGS FROM 2025
ONWARDS AND INCREASE OPERATIONAL AGILITY
* OPERATING PROFIT AMOUNTED TO EUR 368.4 MILLION AND EUR
221.4
MILLION FOR THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024,
RESPECTIVELY
* NET FINANCIAL RESULT FOR THREE AND NINE MONTHS ENDED
SEPTEMBER
30, 2024, AMOUNTED TO EUR 2.2 MILLION AND EUR 8.0 MILLION
* PRE-TAX PROFIT WAS EUR 370.6 MILLION AND EUR 229.4 MILLION
FOR
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024
Source text: ID:nEQ4dDC9va
Further company coverage: 5CV.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))